Darren A E Cross
Overview
Explore the profile of Darren A E Cross including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1797
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hartmaier R, Markovets A, Ahn M, Sequist L, Han J, Cho B, et al.
Cancer Discov
. 2022 Oct;
13(1):98-113.
PMID: 36264123
Significance: The savolitinib + osimertinib combination represents a promising therapy in patients with MET-amplified/overexpressed, EGFRm advanced NSCLC with disease progression on a prior EGFR-TKI. Acquired resistance mechanisms to this combination...
2.
Finlay M, Barton P, Bickerton S, Bista M, Colclough N, Cross D, et al.
J Med Chem
. 2021 Sep;
64(18):13704-13718.
PMID: 34491761
The epidermal growth factor receptor (EGFR) harboring activating mutations is a clinically validated target in non-small-cell lung cancer, and a number of inhibitors of the EGFR tyrosine kinase domain, including...
3.
Colclough N, Chen K, Johnstrom P, Strittmatter N, Yan Y, Wrigley G, et al.
Clin Cancer Res
. 2020 Oct;
27(1):189-201.
PMID: 33028591
Purpose: Osimertinib is a potent and selective EGFR tyrosine kinase inhibitor (EGFR-TKI) of both sensitizing and T790M resistance mutations. To treat metastatic brain disease, blood-brain barrier (BBB) permeability is considered...
4.
Floch N, Lim S, Bickerton S, Ahmed A, Orme J, Urosevic J, et al.
Mol Cancer Ther
. 2020 Sep;
19(11):2298-2307.
PMID: 32943544
Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and T790M-resistance mutations with lower activity against wild-type EGFR and has...
5.
Starrett J, Guernet A, Cuomo M, Poels K, van Alderwerelt van Rosenburgh I, Nagelberg A, et al.
Cancer Res
. 2020 Mar;
80(10):2017-2030.
PMID: 32193290
Osimertinib, a mutant-specific third-generation EGFR tyrosine kinase inhibitor, is emerging as the preferred first-line therapy for -mutant lung cancer, yet resistance inevitably develops in patients. We modeled acquired resistance to...
6.
Blumenthal G, Bunn Jr P, Chaft J, McCoach C, Perez E, Scagliotti G, et al.
J Thorac Oncol
. 2018 Oct;
13(12):1818-1831.
PMID: 30268698
This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung...
7.
Butterworth S, Cross D, Finlay M, Ward R, Waring M
Medchemcomm
. 2018 Aug;
8(5):820-822.
PMID: 30108799
The winners of the Malcolm Campbell Memorial Prize for 2017 discuss the structure-guided discovery of Osimertinib and the difficulties associated with discovering a new drug.
8.
Menard L, Floch N, Martin M, Cross D
Cancer Res
. 2018 Mar;
78(12):3267-3279.
PMID: 29555874
Tyrosine kinase inhibitors (TKI) targeting mutant EGFR in non-small cell lung cancer (NSCLC) have been successful to control cancer growth, but acquired resistance inevitably occurs, including mutations directly on EGFR,...
9.
Floch N, Martin M, Riess J, Orme J, Staniszewska A, Menard L, et al.
Mol Cancer Ther
. 2018 Feb;
17(5):885-896.
PMID: 29483211
EGFR exon 20 insertions (Ex20Ins) account for 4% to 10% of EGFR activating mutations in non-small cell lung cancer (NSCLC). EGFR Ex20Ins tumors are generally unresponsive to first- and second-generation...
10.
Liu S, Li S, Hai J, Wang X, Chen T, Quinn M, et al.
Clin Cancer Res
. 2018 Jan;
24(11):2594-2604.
PMID: 29298799
(or ) aberrations, including both amplification and mutations, have been classified as oncogenic drivers that contribute to 2% to 6% of lung adenocarcinomas. amplification is also an important mechanism for...